Compare DexCom, Inc. (DXCM) vs Eastern Bankshares Inc. Common Stock (EBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Eastern Bankshares Inc. Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.79B). The key difference: DexCom, Inc. is far larger — about 6.7× Eastern Bankshares Inc. Common Stock's market cap, and Eastern Bankshares Inc. Common Stock pays a 2.67% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Eastern Bankshares Inc. Common Stock for 0 Days on average.
| DXCM | EBC | |
|---|---|---|
Market Cap | $32.09B | $4.79B |
Volume | 3,819,730 | 1,740,716 |
Sector | Health | Financials |
52-Week High | $92.34 | $23.65 |
52-Week Low | $54.84 | $16.73 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $5.07B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Eastern Bankshares Inc. Common Stock
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →
